ESSA Pharma Inc.

Equities

EPIX

CA29668H7085

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 07:19:47 23/05/2024 pm IST			5-day change	1st Jan Change
6.015 ^USD	-2.98%		-8.64%	-13.48%

20/05	Top Premarket Decliners	MT
06/03	Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call

ESSA Pharma Inc. Announces Resignation of Frank Perabo as Chief Medical Officer, Effective January 31, 2018

January 26, 2018 at 09:30 am IST

ESSA Pharma Inc. announced that Frank Perabo, M.D., Ph.D., will depart as the company's chief medical officer to pursue other opportunities, effective January 31, 2018. Dr. Perabo will continue to serve the company in an advisory capacity, and as a member of the company's medical advisory committee.

Latest news about ESSA Pharma Inc.

Top Premarket Decliners	20/05	MT
Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call	07/03
Norway's wealth fund pushes for more women on emerging market company boards	06/03	RE
ESSA Pharma Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	13/02	CI
ESSA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	12/12	CI
Essa Pharma Insider Bought Shares Worth $133,274, According to a Recent SEC Filing	24/11	MT
Essa Pharma Insider Bought Shares Worth $419,661, According to a Recent SEC Filing	17/11	MT
ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat	27/23/27	CI
ESSA Pharma Files $200 Million Mixed Shelf	20/23/20	MT
ESSA Pharma Inc. Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer	18/23/18	CI
ESSA Pharma Inc.(NasdaqCM:EPIX) dropped from S&P Global BMI Index	18/23/18	CI
ESSA Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	08/23/08	CI
Essa Pharma Inc. Appoints Lauren Merendino to Its Board of Directors	06/23/06	CI
ESSA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	09/23/09	CI
ESSA Pharma Signs Clinical Trial Support Deal With Janssen to Evaluate EPI-7386 Combinations to Treat Prostate Cancer	12/23/12	MT
ESSA Pharma Inc. Announces Clinical Trial Support Agreement with Janssen Research & Development, LLC	12/23/12	CI
ESSA Pharma Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	07/23/07	CI
Transcript : ESSA Pharma Inc. Presents at B. Riley Securities' 3rd Annual Oncology Conference, Jan-19-2023 11:00 AM	19/23/19
Oppenheimer Adjusts ESSA Pharma's Price Target to $17 From $23, Maintains Outperform Rating	14/22/14	MT
Earnings Flash (EPIX) ESSA PHARMA Posts Q4 Loss $-0.14	13/22/13	MT
ESSA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2022	13/22/13	CI
ESSA Pharma Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	13/22/13	CI
ESSA Pharma, Janssen Suspend Enrollment in Prostate Cancer Treatment Study; ESSA Pharma Shares Sink	31/22/31	MT
Essa Pharma Shares Drop 26% After Janssen Suspends Enrollment for Trials	31/22/31	DJ
ESSA Pharma Inc. Provides an Update on Its Clinical Collaboration with Janssen	31/22/31	CI

Chart ESSA Pharma Inc.

Duration

Period

More charts

Company Profile

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.477 CAD

Average target price

26.69 CAD

Spread / Average Target

+214.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ESSA PHARMA INC.	-13.48%	274M
MODERNA, INC.	+60.60%	62.59B
IQVIA HOLDINGS INC.	-3.00%	41.18B
LONZA GROUP AG	+44.64%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.33%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.77%	19.09B
BIO-TECHNE CORPORATION	+5.27%	13.08B
UNITED THERAPEUTICS CORPORATION	+24.54%	12.26B
MEDPACE HOLDINGS, INC.	+27.52%	12.05B

Other Biotechnology & Medical Research